Mersana Therapeutics appoints Michael A. Metzger as executive VP, COO

Wednesday, April 20, 2011 11:46 AM

Michael A. Metzger has joined Mersana Therapeutics, a platform-based cancer therapeutics company, as executive vice president & chief operating officer. 

Metzger was previously a senior member of the business development team at Forest Laboratories, where he led the company's M&A activities. At Forest, Metzger also completed transformative deals with Cerexa and Novexel, which together formed the cornerstone of Forest's hospital antibiotic franchise. Prior to Forest, Mr. Metzger was vice president of corporate development at Onconova Therapeutics, where he was responsible for the company's business development and financial initiatives.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs